(NASDAQ: TECH) Bio Techne's forecast annual revenue growth rate of 13.75% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 66.72%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.97%.
Bio Techne's revenue in 2023 is $1,117,535,000.On average, 3 Wall Street analysts forecast TECH's revenue for 2023 to be $194,482,115,713, with the lowest TECH revenue forecast at $194,014,346,496, and the highest TECH revenue forecast at $195,128,830,202. On average, 3 Wall Street analysts forecast TECH's revenue for 2024 to be $224,235,063,384, with the lowest TECH revenue forecast at $219,832,381,838, and the highest TECH revenue forecast at $227,605,827,200.
In 2025, TECH is forecast to generate $264,964,576,768 in revenue, with the lowest revenue forecast at $264,964,576,768 and the highest revenue forecast at $264,964,576,768.